65 Spam-Free Article(s) Found
Sort:
Date
Filter:
All
Symbol Name Last Close Mkt Cap DailyStocks'
Rating
Our DailyStocks’ Rating System is a proprietary algorithm that combines the vote of the investor community and legendary trader Richard Dennis’ Turtle Trader System and the System Rules of the Turtle Traders Each day, we generate Buy, Sell, Uptrend or Downtrend signals for 3000 Stocks in the U.S. Markets.
Vote Now!
Wednesday’s Close
LLY Eli Lilly and Company $105.71 $113.53B N/A
Article Searches
Lilly's Olumiant Gets CHMP Nod for Eczema Label Expansion http://www.zacks.com/stock/news/1061199/lillys-olumiant-gets-chmp-nod-for-eczema-label-expansion?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-1061199 Sep 21, 2020 - Eli Lilly's (LLY) label expansion application for Olumiant to include atopic dermatitis in Europe patients gets CHMP recommendation for approval in Europe.
Sorrento Gets FDA Nod for Phase I Study on Coronavirus Antibody http://www.zacks.com/stock/news/1060534/sorrento-gets-fda-nod-for-phase-i-study-on-coronavirus-antibody?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-1060534 Sep 18, 2020 - Sorrento (SRNE) receives an FDA clearance to begin a phase I study on STI-1499 (COVI-GUARD) for treating hospitalized COVID-19 patients. Shares rise.
Lilly, Amgen Ink Manufacturing Deal for Coronavirus Antibodies http://www.zacks.com/stock/news/1060524/lilly-amgen-ink-manufacturing-deal-for-coronavirus-antibodies?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-1060524 Sep 18, 2020 - Eli Lilly (LLY) is developing several potential neutralizing antibodies to treat COVID-19.
Pharma Stock Roundup: AZN, LLY & PFE's Coronavirus Updates, MRK's New Cancer Deals http://www.zacks.com/stock/news/1060523/pharma-stock-roundup-azn-lly-pfes-coronavirus-updates-mrks-new-cancer-deals?cid=CS-ZC-FT-analyst_blog|stock_roundup-1060523 Sep 18, 2020 - AstraZeneca (AZN) resumes its coronavirus vaccine study in the United Kingdom. Merck (MRK) inks two oncology deals with Seattle Genetics.
No Rate Hike Until 2023: Here's How to Play With ETFs http://www.zacks.com/stock/news/1060092/no-rate-hike-until-2023-heres-how-to-play-with-etfs?cid=CS-ZC-FT-etf_news_and_commentary-1060092 Sep 18, 2020 - As widely expected, the Fed held interest rates steady at a near-zero level in its latest meeting.
Roche's Actemra Meets Goal in Phase III Coronavirus Study http://www.zacks.com/stock/news/1060395/roches-actemra-meets-goal-in-phase-iii-coronavirus-study?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-1060395 Sep 18, 2020 - Roche's (RHHBY) phase III study, EMPACTA, evaluating Actemra in patients with COVID-19-associated pneumonia, meets primary endpoint.
Eli Lilly and Co (LLY) Presents at Morgan Stanley Global Healthcare Broker Conference Call - (Transcript) https://seekingalpha.com/article/4374808-eli-lilly-and-co-lly-presents-morgan-stanley-global-healthcare-broker-conference-call?source=feed_sector_healthcare Sep 16, 2020 -
Lilly Drug Gets Fast Track to Improve Heart Attack Outcome http://www.zacks.com/stock/news/1059134/lilly-drug-gets-fast-track-to-improve-heart-attack-outcome?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-1059134 Sep 16, 2020 - Lilly's (LLY) EMPACT-MI study is part of Jardiance's ENPOWER clinical program, which is studying the impact of Jardiance on major clinical cardiovascular and renal outcomes in a spectrum of cardio-renal-metabolic conditions.
Regeneron's Cocktail for Coronavirus Selected for RECOVERY Study http://www.zacks.com/stock/news/1058574/regenerons-cocktail-for-coronavirus-selected-for-recovery-study?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-1058574 Sep 15, 2020 - Regeneron's (REGN) investigational anti-viral antibody cocktail, REGN-COV2, has been selected for evaluation in the RECOVERY study.
Stock Market News for Sep 15, 2020 http://www.zacks.com/stock/news/1058441/stock-market-news-for-sep-15-2020?cid=CS-ZC--market_news-1058441 Sep 15, 2020 - U.S. stock markets closed higher on Monday reversing some of the losses of the last week.

Pages: 1234567

Page 1>